Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis
- PMID: 36934308
- PMCID: PMC10025515
- DOI: 10.1016/j.ygyno.2022.10.015
Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis
Abstract
Background: Limited data from prospective studies suggest that higher dietary intake of long-chain omega-3 polyunsaturated fatty acids (LCn3PUFA), which hold anti-inflammatory properties, may reduce endometrial cancer risk; particularly among certain subgroups characterized by body mass and tumor pathology.
Materials and methods: Data from 12 prospective cohort studies participating in the Epidemiology of Endometrial Cancer Consortium were harmonized as nested case-control studies, including 7268 endometrial cancer cases and 26,133 controls. Habitual diet was assessed by food frequency questionnaire, from which fatty acid intakes were estimated. Two-stage individual-participant data mixed effects meta-analysis estimated adjusted odds ratios (OR) and 95% confidence intervals (CI) through logistic regression for associations between study-specific energy-adjusted quartiles of LCn3PUFA and endometrial cancer risk.
Results: Women with the highest versus lowest estimated dietary intakes of docosahexaenoic acid, the most abundant LCn3PUFA in diet, had a 9% increased endometrial cancer risk (Quartile 4 vs. Quartile 1: OR 1.09, 95% CI: 1.01-1.19; P trend = 0.04). Similar elevated risks were observed for the summary measure of total LCn3PUFA (OR 1.07, 95% CI: 0.99-1.16; P trend = 0.06). Stratified by body mass index, higher intakes of LCn3PUFA were associated with 12-19% increased endometrial cancer risk among overweight/obese women and no increased risk among normal-weight women. Higher associations appeared restricted to White women. The results did not differ by cancer grade.
Conclusion: Higher dietary intakes of LCn3PUFA are unlikely to reduce endometrial cancer incidence; rather, they may be associated with small to moderate increases in risk in some subgroups of women, particularly overweight/obese women.
Keywords: Endometrial cancer; Fatty acid; Omega-3; Polyunsaturated; Uterine cancer.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a cancer journal for clinicians. 2021;71:7–33. - PubMed
-
- Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev. 2013;22:233–41. - PubMed
-
- Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975–2018. Bethesda, MD: National Cancer Institute; 2021.
-
- Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women. Cancer Epidemiol Biomarkers Prev. 2015;24:1407–15. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA118100/CA/NCI NIH HHS/United States
- P30 CA016056/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- U01 CA250476/CA/NCI NIH HHS/United States
- R01 CA058598/CA/NCI NIH HHS/United States
- HHSN268201100046C/HL/NHLBI NIH HHS/United States
- HHSN268201100003C/WH/WHI NIH HHS/United States
- ZIA CP010196/ImNIH/Intramural NIH HHS/United States
- HHSN268201000046C/HL/NHLBI NIH HHS/United States
- P01 CA033619/CA/NCI NIH HHS/United States
- HHSN268201100002C/WH/WHI NIH HHS/United States
- R01 CA098346/CA/NCI NIH HHS/United States
- Z01 CP010196/ImNIH/Intramural NIH HHS/United States
- HHSN268201100003I/HL/NHLBI NIH HHS/United States
- HHSN268201100002I/HL/NHLBI NIH HHS/United States
- U01 CA202979/CA/NCI NIH HHS/United States
- U01 CA164974/CA/NCI NIH HHS/United States
- R03 CA212808/CA/NCI NIH HHS/United States
- HHSN268201100004I/HL/NHLBI NIH HHS/United States
- R01 CA082838/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- R03 CA135632/CA/NCI NIH HHS/United States
- R01 CA058420/CA/NCI NIH HHS/United States
- HHSN268201100006C/HL/NHLBI NIH HHS/United States
- R01 CA039742/CA/NCI NIH HHS/United States
- R01 CA083918/CA/NCI NIH HHS/United States
- P30 CA071789/CA/NCI NIH HHS/United States
- U01 CA164973/CA/NCI NIH HHS/United States
- HHSN268201100004C/WH/WHI NIH HHS/United States
- R03 CA169888/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
